States sue Biden over COVID vaccine mandate

President Joe Biden is facing major backlash following a COVID-19 vaccine mandate.

After at least two dozen states filed lawsuits against the rule, a federal appeals court has blocked it. The rule mandates all private employers with more than 100 employees to require all employees to be vaccinated against COVID-19 by Jan. 4, 2022, or test weekly for the virus. Employers are also required to mandate masks for unvaccinated employees by Dec. 5.

With the rule on pause at the moment, the trajectory of the mandate is uncertain. Several healthcare companies have already implemented their own vaccine mandates, though a portion of healthcare professionals have noted they won’t get vaccinated. Some healthcare providers have struggled with the decision whether or not to require vaccination for staff.

The court decision that paused the rule was made by the 5th Circuit Court of Appeals, which stated the states suing "give cause to believe there are grave statutory and constitutional issues with the Mandate,” NPR reported. There are multiple lawsuits across the courts that will likely be consolidated in the coming weeks.

However, even with the pause––and potential for the rule to be permanently shut down in the courts––many healthcare companies and larger companies outside the healthcare industry are likely to take up the mandate on their own.

 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.